Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: Advanced brain PET imaging for glioma assessment, reflecting how Telix Pharmaceuticals Limited’s TLX101-Px could expand standardized FET-PET access for brain cancer diagnosis and treatment decision-making in Europe.
Medical Devices & Diagnostics

Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane

Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.

Read More
Representative image: An ophthalmology clinic scene showing retinal imaging and eye examination technology, reflecting Kodiak Sciences’ KSI-101 clinical data in macular edema secondary to inflammation and the growing role of biologics in inflammatory retinal disease treatment.
Pharma & Biotech

Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?

Steroids still dominate MESI care. Kodiak’s KSI-101 may test whether local biologics can change inflammatory retina treatment.

Read More
Representative image of a microneedle catheter concept for targeted intratumoral drug delivery in pancreatic cancer, reflecting Vector Science & Therapeutics’ early-stage research into localized oncology treatment platforms.
Medical Devices & Diagnostics

Can Vector Science’s microneedle catheter patent crack one of oncology’s hardest delivery problems?

Pancreatic cancer needs local precision. Vector Science is betting a catheter patent can move drug delivery closer to the tumor.

Read More
Representative image of a modern ophthalmology research setting showing tablet-based contrast sensitivity testing, reflecting PerZeption Inc.’s AIM+ CSF collaboration with Alcon Research to advance faster digital vision assessment.
Medical Devices & Diagnostics

Can PerZeption and Alcon make contrast sensitivity testing faster for vision correction research?

Vision testing is getting faster. PerZeption and Alcon now face the harder test: proving AIM+ CSF can reshape research-grade evidence.

Read More
Representative image: A ferry passenger experiencing motion sickness, reflecting Vanda Pharmaceuticals Inc.’s U.S. launch of NEREUS as a new prescription treatment option for adults with vomiting induced by motion.
Pharma & Biotech

Can direct to consumer access help Vanda scale NEREUS beyond niche travel use?

Motion sickness finally has a new prescription drug. Vanda’s test is whether NEREUS can move beyond travel novelty into real demand.

Read More
Representative image: Pediatric endocrine care is drawing renewed attention as Neurocrine Biosciences’ CRENESSITY two-year CAHtalyst Pediatric data show durable hormone control, reduced glucocorticoid exposure and potential long-term clinical benefits for children with classic congenital adrenal hyperplasia.
Pharma & Biotech

Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability

Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.

Read More
Representative image: Generic semaglutide injection pens and diabetes-care materials illustrate Apotex’s Health Canada approval for Apo-Semaglutide Injection, a generic Ozempic equivalent that could reshape GLP-1 access and diabetes treatment affordability in Canada.
Pharma & Biotech

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More
139th Canton Fair Phase 3 puts smart healthcare and technical fabrics at the centre of China’s next export story
Medical Devices & Diagnostics

Why China’s Canton Fair is quietly turning medical robots and smart fabrics into its next global trade pitch

China’s export pitch is moving upmarket. Canton Fair Phase 3 puts smart healthcare and adaptive fabrics at the centre of that shift.

Read More
Representative image: Ophthalmology researchers evaluate retinal imaging data as Spinogenix’s tazbentetol preclinical results raise new questions about synaptic regeneration, glaucoma neuroprotection, and diabetic retinopathy treatment strategies.
Pharma & Biotech

Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research

Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.

Read More